FINWIRES · TerminalLIVE
FINWIRES

Hanall Biopharma Loses Arbitration Bid to Terminate HL161 License with Harbour BioMed

By

Hanall Biopharma's (KRX:009420) said an International Chamber of Commerce arbitral tribunal has ruled that the termination notice issued by the company was invalid, upholding the existing license agreement with Harbor Biomed for HL161 (Batoclimab) in China.

The final decision, confirmed on Tuesday, means the partnership remains unchanged despite the Hanall Biopharma's earlier attempt to dissolve the contract, according to a bourse filing on Wednesday.

The ruling does not disrupt the ongoing regulatory approval and commercialization of Batoclimab for generalized myasthenia gravis in China, which continues under the original terms.

This outcome resolves a dispute first announced in March 2025, allowing the collaboration to proceed as initially agreed.

Related Articles

Asia

Aedge Group Unit to Buy Commercial Property for SG$7.5 Million

Aedge Group's (SGX:XVG) subsidiary, IPF Investments, exercised an option to acquire a freehold property in Singapore for SG$7.5 million, according to a Monday bourse filing.The property has a land area of around 297.4 square meters and is currently tenanted at a monthly rent of SG$20,000.The acquisition will be funded through a combination of internal resources and bank borrowings and is expected to be completed on or before Oct. 13.

SGX:XVG
Asia

Huadian New Energy's Power Generation Rises 24% in Q2

Huadian New Energy's (SHA:600930) power generation in the second quarter rose 24% year on year to 36.2 billion kilowatt-hours, according to a Shanghai bourse filing on Tuesday.The increase was mainly attributable to the commissioning of additional installed generating capacity, with 2.39 million kilowatts being added during the quarter.For the first half, the power company's power generation climbed 22% to 69.1 billion kWh from a year earlier.The company's shares fell 3% during the morning trade.

SHA:600930
Asia

Giga Device Semiconductor Sees No Reason for Stock Surge; Shares Rise 9%

Giga Device Semiconductor's (HKG:3986, SHA:603986) stock deviated by more than 20% across three straight trading sessions on July 16, 17, and 20, according to a Tuesday filing with the Shanghai bourse.Following an internal investigation and verification with its controlling shareholder and actual controller, the company said it has no undisclosed material information, plans, or negotiations that may have had a significant impact on its stock price.The company's shares jumped 9% recently.

SHA:603986